Normal IDH2R140Q (N = 67, 83.7%) | Heterozygous IDH2R140Q mutation (N = 13, 16.3%) | p value*# | ||
---|---|---|---|---|
Age (years) | Mean ± SD | 42.6 ± 16.0 | 57.2 ± 8.5 | 0.002 |
Gender | N (%) | 0.950 | ||
Male | 47 (70.1) | 9 (69.3) | ||
Female | 20 (29.9) | 4 (30.7) | ||
Hepatomegaly | N (%) | 0.221 | ||
Negative | 34 (50.7) | 9 (69.3) | ||
Positive | 33 (49.3) | 4 (30.7) | ||
Splenomegaly | N (%) | 0.149 | ||
Negative | 22 (32.8) | 7 (53.8) | ||
Positive | 45 (67.2) | 6 (46.2) | ||
Lymphadenopathy | N (%) | 0.037 | ||
Negative | 42 (62.7) | 12 (92.3) | ||
Positive | 25 (37.3) | 1 (7.7) | ||
Hemoglobin (g/dl) | Mean ± SD | 6.7 ± 1.5 | 7.3 ± 2.2 | 0.228 |
TLC (× 109/L) | Mean ± SD | 77.9.4 ± 39.1 | 22.2 ± 15.6 | < 0.001 |
Platelets (× 109/L) | Mean ± SD | 25.9 ± 13.2 | 49.1 ± 22.7 | < 0.001 |
Blast cells (%) | Mean ± SD | 70.4 ± 21.0 | 81.3 ± 7.4 | 0.069 |
FAB classification | N (%) | 0.439 | ||
M1 | 11 (16.4) | 0 (0) | ||
M2 | 35 (52.2) | 9 (69.2) | ||
M4 | 16 (23.8) | 3 (23.1) | ||
M5 | 5 (7.6) | 1 (7.7) | ||
IDH1SNPrs11554137 | N (%) | 0.488 | ||
Normal | 57 (85.1) | 12 (92.3) | ||
Heterozygous | 10 (14.9) | 1 (7.7) | ||
Outcome at 28 days | N (%) | 0.010 | ||
Favorable+ | 18 (26.9) | 0 (0) | ||
Unfavorable++ | 49 (73.1) | 13 (100) | ||
Outcome at 6 months | N (%) | 0.146 | ||
Favorable+ | 30 (44.8) | 3 (23.1) | ||
Unfavorable+++ | 37 (55.2) | 10 (76.9) | ||
Median survival (days) | Median (IQR) | 160 (25–170) | 14 (9–55) | 0.027 |